Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
- PMID: 33731853
- PMCID: PMC7966918
- DOI: 10.1038/s41422-021-00487-9
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
Abstract
Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against coronavirus disease 2019 (COVID-19). We isolated a large number of nAbs from SARS-CoV-2-infected individuals capable of disrupting proper interaction between the receptor binding domain (RBD) of the viral spike (S) protein and the receptor angiotensin converting enzyme 2 (ACE2). However, the structural basis for their potent neutralizing activity remains unclear. Here, we report cryo-EM structures of the ten most potent nAbs in their native full-length IgG-form or in both IgG-form and Fab-form bound to the trimeric S protein of SARS-CoV-2. The bivalent binding of the full-length IgG is found to associate with more RBDs in the "up" conformation than the monovalent binding of Fab, perhaps contributing to the enhanced neutralizing activity of IgG and triggering more shedding of the S1 subunit from the S protein. Comparison of a large number of nAbs identified common and unique structural features associated with their potent neutralizing activities. This work provides a structural basis for further understanding the mechanism of nAbs, especially through revealing the bivalent binding and its correlation with more potent neutralization and the shedding of S1 subunit.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13. Microbiol Spectr. 2021. PMID: 34643438 Free PMC article.
-
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.Front Immunol. 2021 Jun 4;12:691715. doi: 10.3389/fimmu.2021.691715. eCollection 2021. Front Immunol. 2021. PMID: 34149735 Free PMC article.
-
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.Nature. 2020 Dec;588(7839):682-687. doi: 10.1038/s41586-020-2852-1. Epub 2020 Oct 12. Nature. 2020. PMID: 33045718 Free PMC article.
-
A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.Front Immunol. 2021 Apr 28;12:647934. doi: 10.3389/fimmu.2021.647934. eCollection 2021. Front Immunol. 2021. PMID: 33995366 Free PMC article. Review.
-
Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies.Curr Med Sci. 2021 Dec;41(6):1065-1074. doi: 10.1007/s11596-021-2453-8. Epub 2021 Oct 4. Curr Med Sci. 2021. PMID: 34606064 Free PMC article. Review.
Cited by
-
Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies.Comput Struct Biotechnol J. 2022;20:2212-2222. doi: 10.1016/j.csbj.2022.04.038. Epub 2022 May 2. Comput Struct Biotechnol J. 2022. PMID: 35530743 Free PMC article.
-
Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization.J Clin Virol. 2022 Jun;150-151:105162. doi: 10.1016/j.jcv.2022.105162. Epub 2022 Apr 14. J Clin Virol. 2022. PMID: 35461042 Free PMC article.
-
Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19.Trends Biotechnol. 2023 Apr;41(4):528-544. doi: 10.1016/j.tibtech.2022.07.012. Epub 2022 Aug 1. Trends Biotechnol. 2023. PMID: 35995601 Free PMC article. Review.
-
In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies.Pharmaceutics. 2021 Nov 6;13(11):1882. doi: 10.3390/pharmaceutics13111882. Pharmaceutics. 2021. PMID: 34834297 Free PMC article. Review.
-
Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.Adv Sci (Weinh). 2022 Jan;9(1):e2102181. doi: 10.1002/advs.202102181. Epub 2021 Oct 29. Adv Sci (Weinh). 2022. PMID: 34716683 Free PMC article.
References
-
- Ksiazek TG, et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953–1966. - PubMed
-
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012;367:1814–1820. - PubMed
-
- Lan J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–220. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
